RxDoctor Payments Data

Bryan Bowen, MD

Family Medicine · Wake Village, TXNPI 1770578072

Payments from drug & device makers

$13,499in general payments, 2019–2025

Across 965 payments — averaging $13.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$1K
  • Novo Nordisk$888
  • AstraZeneca$779
  • Amgen$639
  • Abbott$633
  • plus $7K from 50 others

What the payments were for

  • Food & beverage$13,19298%
  • Education$2892%
  • Other$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)221$2,470
Lilly USA, LLC103$1,089
Novo Nordisk88$888
AstraZeneca44$779
Amgen(2 entities)42$639
Abbott34$633
Pfizer41$608
Boehringer Ingelheim41$591
Merck30$447
Novartis24$433
Amarin Pharma, Inc.25$407
Astellas Pharma US Inc14$393
GSK30$393
Takeda Pharmaceuticals U.S.A., Inc.24$302
Johnson & Johnson17$261
Phathom Pharmaceuticals, Inc.14$237
Sanofi-aventis U.S. LLC17$205
Genentech USA, Inc.13$191
Otsuka America Pharmaceutical, Inc.8$185
Bayer14$181
Supernus Pharmaceuticals, Inc.9$172
Idorsia Pharmaceuticals US Inc10$151
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC9$137
Kowa Pharmaceuticals America, Inc.9$136
Antares Pharma, Inc.7$130
Biohaven Pharmaceutical Holding Company Ltd.3$123
Lundbeck LLC5$111
Eisai Inc.7$103
Biohaven Pharmaceuticals, Inc.5$98
E.r. Squibb & Sons, L.L.C.7$96
Teva Pharmaceuticals USA, Inc.5$89
Corcept Therapeutics3$87
Exact Sciences4$80
Currax Pharmaceuticals LLC4$70
Dexcom, Inc.3$54
Xeris Pharmaceuticals, Inc.3$49
Evoke Pharma, Inc.2$39
Almatica Pharma LLC2$38
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$36
Esperion Therapeutics, Inc.2$32
Pharmacyclics LLC, An Abbvie Company1$30
Arbor Pharmaceuticals, Inc.2$29
Mylan Specialty L.p.2$26
Jazz Pharmaceuticals Inc.1$25
Biodelivery Sciences International, Inc.2$25
Halozyme Inc1$24
Avanir Pharmaceuticals, Inc.2$24
Daiichi Sankyo Inc.1$23
Viatris Specialty LLC1$23
Baxter Healthcare1$19
Nalpropion Pharmaceuticals LLC1$16
Ironshore Pharmaceuticals Inc.1$16
Smith+Nephew1$15
Atricure, Inc.1$15
Sumitomo Pharma America, Inc.1$15
Melinta Therapeutics, LLC1$12

How this compares

$13,499 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$357,927
Medicare patients
638
Services billed
10,031

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide87$114,912
OzempicSemaglutide104$110,505
FarxigaDapagliflozin Propanediol110$89,109
EliquisApixaban92$88,019
JardianceEmpagliflozin40$43,483
JanuviaSitagliptin Phosphate34$38,433
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$34,634
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog23$28,438
XareltoRivaroxaban23$25,756
Tresiba Flextouch U-200Insulin Degludec25$19,788
Soliqua 100-33Insulin Glargine/Lixisenatide18$17,935
MyrbetriqMirabegron24$13,003
Fiasp FlextouchInsulin Aspart (Niacinamide)13$12,532
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog21$10,418
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen355$9,117

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$1,089$114,91287 claims
Novo NordiskOzempic$888$110,505104 claims
AstraZenecaFarxiga$779$89,109110 claims
PfizerEliquis$608$88,01992 claims
Boehringer IngelheimJardiance, Tradjenta$591$48,96451 claims
MerckJanuvia$447$38,43334 claims
GSKTrelegy Ellipta$393$34,63443 claims
Johnson & JohnsonXarelto$261$25,75623 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$205$17,93518 claims
Astellas Pharma US IncMyrbetriq$393$13,00324 claims
AbbVieSynthroid$2,470$3,35645 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Wake Village

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →